Paper Details

  1. Home
  2. Paper Details

AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.

Author: CadyRoger K, DjupeslandPer G, MahmoudRamy A, MessinaJohn, ShinPaul, SiffertJoao, SilbersteinStephen, TepperStewart J

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the efficacy, tolerability, and safety of AVP-825, an investigational bi-directional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder, versus 100 mg oral sumatriptan for acute treatment of migraine.
Paper Details　
Original Abstract of the Article :
The objective of this study was to compare the efficacy, tolerability, and safety of AVP-825, an investigational bi-directional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder, vs 100 mg oral sumatriptan for acute treatment of migraine in a double-dummy, rand...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682470/

データ提供：米国国立医学図書館（NLM）

AVP-825 for Migraines: A Camel's Quest for Relief

This clinical trial examines the effectiveness of AVP-825, a new intranasal delivery system for sumatriptan, in treating migraines. Imagine a camel, its head throbbing with a migraine, seeking relief from a new treatment. This research compares AVP-825 to oral sumatriptan, aiming to find a faster and more effective way to combat the debilitating effects of migraines.

AVP-825: A Potential Shortcut Through the Migraine Desert

The study reveals promising results for AVP-825, suggesting it may be a viable option for treating migraines, perhaps even faster and more tolerable than traditional oral medications. This discovery is like a camel finding a shortcut through a vast and treacherous desert, offering a more efficient way to reach its destination.

Navigating the Desert of Migraines

Migraines, like a relentless sandstorm, can disrupt daily life. This research provides a glimmer of hope, suggesting that AVP-825 may offer a faster and more comfortable way to combat these debilitating headaches. However, it is essential to consult with your doctor to determine if AVP-825 is the right treatment for you.

Dr. Camel's Conclusion

This clinical trial explores a new path in the desert of migraine treatment, suggesting AVP-825 may offer a more efficient and effective solution. As a camel traveler seeking respite from the harsh desert sun, I am encouraged by this potential advancement in migraine care. With continued research and understanding, we may find even more effective ways to navigate the challenging terrain of migraine headaches.
Date :
  1. Date Completed 2016-04-01
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

25941016

DOI: Digital Object Identifier

PMC4682470

Related Literature

Article Analysis
・Effects of sumatriptan nasal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.